Rigel Pharmaceuticals, Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

NET INCOME (LOSS) PER SHARE

NET INCOME (LOSS) PER SHARE

3 Months Ended

Mar. 31, 2025

2.	Net Income (Loss) Per Share

The following table sets forth the computation of basic and diluted earnings per share (in thousands except per share amounts):


	Three Months Ended March 31,
	2025		2024
EPS Numerator:
Net income (loss)	$	11,446	$	(8,247)
EPS Denominator—Basic:
Weighted-average common shares outstanding		17,808		17,520
EPS Denominator—Diluted:
Weighted-average common shares outstanding		17,808		17,520
Dilutive effect of stock options, RSUs and shares under Purchase Plan		361		—
Weighted-average shares outstanding and common stock equivalents		18,169		17,520

Net income (loss) per share
Basic	$	0.64	$	(0.47)
Diluted	$	0.63	$	(0.47)

The potential shares of common stock that were excluded from the computation of diluted net income (loss) per share for the periods presented because including them would have been antidilutive are as follows (in thousands):


	Three Months Ended March 31,
	2025		2024
Stock options		2,582		3,713
RSUs		231		407
Shares under Purchase Plan		25		24
Total		2,838		4,144